Back to Report Store Home

Global Urological Cancer Market to 2022 - Strong Growth Driven by Rising Prevalence, Increased Uptake of Hormone Therapies and Approval of Novel Biologics

  • Published: Jun-2016
  • Report Code: GBIHC412MR
  • Report Format: pdf

Description

Table of Contents

1 Table of Contents 4

1.1 List of Tables 6

1.2 List of Figures 6

2 Introduction 9

2.1 Disease Cluster Introduction 9

2.2 Symptoms 9

2.3 Etiology and Pathophysiology 10

2.3.1 Etiology 10

2.3.2 Pathophysiology 12

2.4 Co-morbidities and Complications 13

2.5 Epidemiology Patterns; Prevalence, Patient Segmentation, and Diagnostic and Treatment Usage Rates 13

2.5.1 Bladder Cancer 14

2.5.2 Kidney Cancer 15

2.5.3 Prostate Cancer 16

2.5.4 Testicular Cancer 17

2.6 Treatment 18

2.6.1 Chemotherapy 18

2.6.2 Surgery and Radiation Therapy 20

2.6.3 Hormonal Therapies 22

2.6.4 Targeted Therapies 23

3 Key Marketed Products 25

3.1 Overview 25

3.2 Zytiga (abiraterone acetate) 25

3.3 Xtandi (enzalutamide) 27

3.4 Sutent (sunitinib malate) 28

3.5 Votrient (pazopanib hydrochloride) 29

3.6 Inlyta (axitinib) 30

3.7 Jevtana (cabazitaxel) 31

3.8 Xofigo (radium Ra 223 dichloride) 33

3.9 Provenge (sipuleucel-T) 34

3.10 Opdivo (nivolumab) – Bristol-Myers Squibb 35

3.11 Conclusion 37

4 Pipeline Landscape Assessment 38

4.1 Overview 38

4.2 Pipeline Development Landscape 39

4.3 Molecular Targets in the Pipeline 42

4.4 Clinical Trials 46

4.4.1 Failure Rate by Stage of Development, Indication, Molecule Type and Molecular Target 47

4.4.2 Clinical Trial Duration by Stage of Development, Indication, Molecule Type and Molecular Target 51

4.4.3 Clinical Trial Size by Stage of Development, Indication, Molecule Type and Molecular Target 55

4.4.4 Aggregate Clinical Program Size by Stage of Development, Indication, Molecule Type and Molecular Target 59

4.5 Conclusion 63

4.6 Assessment of Key Pipeline Products 64

4.6.1 Atezolizumab – Roche 64

4.6.2 Durvalumab – AstraZeneca 65

4.6.3 Durvalumab + Tremelimumab – MedImmune 66

4.6.4 Apalutamide – Johnson & Johnson 67

4.6.5 Avelumab – Merck KGaA 68

4.6.6 Tivozanib – EUSA Pharma 69

4.6.7 Eoquin – Spectrum Pharmaceuticals 70

4.6.8 Prostvac – Bavarian Nordic 71

4.7 Conclusion 72

5 Multi-Scenario Market Forecast to 2022 73

5.1 Overall Market Size 73

5.2 Generic Penetration 75

5.3 Revenue Forecast by Molecular Target 78

5.3.1 Androgen Receptor Antagonists 78

5.3.2 Programmed Cell Death Protein 1 Inhibitor 78

5.3.3 VEGF Inhibitors 79

5.3.4 GnRH Inhibitors 80

5.3.5 Tubulin Inhibitors 81

5.3.6 CTLA-4 Inhibitors 82

6 Company Analysis and Positioning 83

6.1 Revenue and Market Share Analysis by Company 84

6.1.1 Pfizer – Will a Patent Cliff Be Avoided Following the Expiries of Sutent and Inlyta? 88

6.1.2 Novartis – How Will Upcoming Patent Expiries Affect Urological Cancer Revenues? 89

6.1.3 Johnson & Johnson – How Will Zytiga Perform in an Increasingly Competitive Prostate Cancer Treatment Market? 90

6.1.4 Astellas – What Will Become of Xtandi? 91

6.1.5 AstraZeneca – Will Sales Revenues Increase over the Forecast Period? 92

6.1.6 Bristol-Myers Squibb – How Will Cancer Immunotherapies Affect Urological Cancers? 93

6.2 Company Landscape 94

6.3 Marketed and Pipeline Portfolio Analysis 95

7 Strategic Consolidations 99

7.1 Licensing Deals 99

7.1.1 Deals by Region, Year and Value 99

7.1.2 Deals by Stage of Development and Value 101

7.1.3 Deals by Molecule Type, Molecular Target and Value 102

7.1.4 Table for Licensing Deals Valued Above $100m 104

7.2 Co-development Deals 106

7.2.1 Deals by Region, Year and Value 106

7.2.2 Deals by Stage of Development and Value 107

7.2.3 Deals by Molecule Type, Molecular Target and Value 108

8 Appendix 111

8.1 References 111

8.2 Table of All Clinical Stage Pipeline Products 127

8.3 Abbreviations 145

8.4 Methodology 146

8.4.1 Coverage 146

8.4.2 Secondary Research 146

8.4.3 Market Size and Revenue Forecasts 147

8.4.4 Pipeline Analysis 147

8.4.5 Competitive Landscape 147

8.5 Contact Us 148

8.6 Disclaimer 148

License Details
Electronic PDF copy delivered via email. Report can be used by individual purchaser only.
Single User Licence
$4995
Electronic PDF copy delivered via email. Report can be shared by unlimited users within one corporate location, e.g. a regional office.
Site Licence
$9990
Electronic PDF copy delivered via email. Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company.
Global Licence
$14985
Email to a colleague Enquire Before Buying
Prefer to speak to a team member? Call us on:
+44 161 359 5414
Or click here to contact us
Secure Payments
Cards